Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma D Johnson

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Lancet. Respiratory Medicine|January 25, 2024
Optimising antibiotic treatment duration in ventilator-associated pneumoniaEmma D Johnson, James D Chalmers
Expert Review of Respiratory Medicine|November 4, 2024
What is the future of inhaled antibiotics for bronchiectasis?Emma D Johnson, James D Chalmers
European Respiratory Review : an Official Journal of the European Respiratory Society|July 24, 2024
Exacerbations of bronchiectasisAlessandro De Angelis, Emma D Johnson, Sivagurunathan Sutharsan, et al.
American Journal of Respiratory and Critical Care Medicine|July 15, 2025
Endotypes of <i>Pseudomonas aeruginosa</i> Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4)Rebecca C Hull, Jamie Stobo, Hani Abo-Leyah, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
The Lancet. Respiratory Medicine|August 30, 2025
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational studyOriol Sibila, Jamie Stobo, Lidia Perea, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Lancet. Respiratory Medicine|January 25, 2024
Optimising antibiotic treatment duration in ventilator-associated pneumoniaEmma D Johnson, James D Chalmers
Expert Review of Respiratory Medicine|November 4, 2024
What is the future of inhaled antibiotics for bronchiectasis?Emma D Johnson, James D Chalmers
European Respiratory Review : an Official Journal of the European Respiratory Society|July 24, 2024
Exacerbations of bronchiectasisAlessandro De Angelis, Emma D Johnson, Sivagurunathan Sutharsan, et al.
American Journal of Respiratory and Critical Care Medicine|July 15, 2025
Endotypes of <i>Pseudomonas aeruginosa</i> Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4)Rebecca C Hull, Jamie Stobo, Hani Abo-Leyah, et al.
American Journal of Respiratory and Critical Care Medicine|February 12, 2025
Broad Immunomodulatory Effects of the Dipeptidyl-peptidase-1 Inhibitor Brensocatib in Bronchiectasis: Data from the Phase 2, Double-Blind, Placebo-controlled WILLOW TrialEmma D Johnson, Merete B Long, Lidia Perea, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
The Lancet. Respiratory Medicine|August 30, 2025
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational studyOriol Sibila, Jamie Stobo, Lidia Perea, et al.
Pageof 1